Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma
- 366 Downloads
Few studies evaluated the prognostic value of the presence of lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC).
The association between LVI and survival was evaluated in a cohort of BC patients treated by NAC between 2002 and 2011. Five post-NAC prognostic scores (ypAJCC, RCB, CPS, CPS + EG and Neo-Bioscore) were evaluated and compared with or without the addition of LVI.
Out of 1033 tumors, LVI was present on surgical specimens in 29.2% and absent in 70.8% of the cases. Post-NAC LVI was associated with impaired disease-free survival (DFS) (HR 2.54; 95% CI 1.96–3.31; P < 0.001), and the magnitude of this effect depended on BC subtype (Pinteraction = 0.003), (luminal BC: HR 1.83; P = 0.003; triple negative BC: HR 3.73; P < 0.001; HER2-positive BC: HR 6.21; P < 0.001). Post-NAC LVI was an independent predictor of local relapse, distant metastasis, and overall survival; and increased the accuracy of all five post-NAC prognostic scoring systems.
Post-NAC LVI is a strong independent prognostic factor that: (i) should be systematically reported in pathology reports; (ii) should be used as stratification factor after NAC to propose inclusion in second-line trials or adjuvant treatment; (iii) should be included in post-NAC scoring systems.
KeywordsBreast carcinoma Lymphovascular invasion Neoadjuvant chemotherapy Prognostic scores
Akaike information criterion
Body mass index (kg/m2)
Ductal carcinoma in situ
Nottingham Clinico-Pathological Response Index
No specific type
Pathological complete response
Residual cancer burden
Triple negative breast cancer
We thank Roche* France for financial support for construction of the Institut Curie neoadjuvant database (NEOREP). The funding source had no role in data analysis and interpretation neither in writing the manuscript. AS Hamy was supported by an ITMO-INSERM-AVIESAN cancer translational research grant.
This work was supported by the Site de Recherche Intégrée en Cancérologie/Institut National du Cancer (INCa-DGOS-4654); and Grant ARC Fundation 2013 (SL220130607090).
Compliance with ethical standards
Conflict of interest
This report describes an original work and is not under consideration by any other journal. All authors approved the manuscript and this submission. There are no conflicts of interest.
- 7.NCCN Evidence Blocks, TM (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - Breast Cancer., 2016Google Scholar
- 8.Coates AS, Winer EP, Goldhirsch A et al (2015) Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol Off J Eur Soc Med Oncol 26:1533–1546. https://doi.org/10.1093/annonc/mdv221 CrossRefGoogle Scholar
- 11.Edge S, Byrd D, Compton C, et al (2009) American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th ednGoogle Scholar
- 14.Mittendorf EA, Vila J, Tucker SL et al (2016) The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment. JAMA Oncol 2:929–936. https://doi.org/10.1001/jamaoncol.2015.6478 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.R Development Core Team (2011) R: a language and environment for statistical computing. R Foundation for Statistical ComputingGoogle Scholar
- 16.Abdel-Fatah TM, Ball G, Lee AHS et al (2015) Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer. Clin Cancer Res 21:1052–1062. https://doi.org/10.1158/1078-0432.CCR-14-0685 CrossRefPubMedGoogle Scholar
- 24.Provenzano E, Bossuyt V, Viale G, et al (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28:1185–201. https://doi.org/10.1038/modpathol.2015.74